{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T00:45:59Z","timestamp":1794357959230,"version":"4.9.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T00:00:00Z","timestamp":1551830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1038\/s41416-019-0415-8","type":"journal-article","created":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T00:09:56Z","timestamp":1551830996000},"page":"697-702","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Can we classify ampullary tumours better? Clinical, pathological and molecular features. Results of an AGEO study"],"prefix":"10.1038","volume":"120","author":[{"given":"Geraldine","family":"Perkins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Svrcek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile","family":"Bouchet-Doumenq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibault","family":"Voron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orianne","family":"Colussi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clotilde","family":"Debove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatiha","family":"Merabtene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Dumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Sauvanet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Hammel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Cros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Baptiste","family":"Bachet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armelle","family":"Bardier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Douard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tchao","family":"Meatchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederique","family":"Peschaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Francois","family":"Emile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Cojean-Zelek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Laurent-Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Taieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,6]]},"reference":[{"key":"415_CR1","unstructured":"Edge S. B., American Joint Committee on Cancer, American Cancer Society (eds.). AJCC cancer staging handbook: from the AJCC cancer staging manual. 7th ed. Springer: New York, 2010."},{"key":"415_CR2","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1097\/MPA.0000000000000112","volume":"43","author":"PE Robert","year":"2014","unstructured":"Robert, P.-E. et al. Predictors of long-term survival following resection for ampullary carcinoma: a large retrospective French multicentric study. Pancreas 43, 692\u2013697 (2014).","journal-title":"Pancreas"},{"key":"415_CR3","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/jso.22090","volume":"105","author":"WS Kim","year":"2012","unstructured":"Kim, W. S. et al. Clinical significance of pathologic subtype in curatively resected ampulla of vater cancer: Ampulla of Vater Cancer. J. Surg. Oncol. 105, 266\u2013272 (2012).","journal-title":"J. Surg. Oncol."},{"key":"415_CR4","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.ejso.2015.01.010","volume":"41","author":"O Colussi","year":"2015","unstructured":"Colussi, O. et al. Prognostic score for recurrence after Whipple\u2019s pancreaticoduodenectomy for ampullary carcinomas; results of an AGEO retrospective multicenter cohort. Eur. J. Surg. Oncol. EJSO 41, 520\u2013526 (2015).","journal-title":"Eur. J. Surg. Oncol. EJSO"},{"key":"415_CR5","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1097\/PAS.0000000000000230","volume":"38","author":"DC Ang","year":"2014","unstructured":"Ang, D. C., Shia, J., Tang, L. H., Katabi, N. & Klimstra, D. S. The utility of immunohistochemistry in subtyping adenocarcinoma of the ampulla of vater. Am. J. Surg. Pathol. 38, 1371\u20131379 (2014).","journal-title":"Am. J. Surg. Pathol."},{"key":"415_CR6","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1200\/JCO.2012.46.8868","volume":"31","author":"DK Chang","year":"2013","unstructured":"Chang, D. K. et al. Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater. J. Clin. Oncol. 31, 1348\u20131356 (2013).","journal-title":"J. Clin. Oncol."},{"key":"415_CR7","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/bjc.2015.172","volume":"113","author":"A Schueneman","year":"2015","unstructured":"Schueneman, A. et al. Validation of histomolecular classification utilizing histological subtype, MUC1 and CDX2 for prognostication of resected ampullary adenocarcinoma. Br. J. Cancer 113, 64\u201368 (2015).","journal-title":"Br. J. Cancer"},{"key":"415_CR8","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1136\/jclinpath-2015-203337","volume":"69","author":"JM Leo","year":"2016","unstructured":"Leo, J. M. et al. Immunophenotyping of ampullary carcinomata allows for stratification of treatment specific subgroups. J. Clin. Pathol. 69, 431\u2013439 (2016).","journal-title":"J. Clin. Pathol."},{"key":"415_CR9","doi-asserted-by":"publisher","unstructured":"Yun S. P., Seo H. I. Prognostic impact of immunohistochemical expression of CK7 and CK20 in curatively resected ampulla of Vater cancer. BMC. Gastroenterol. 2015; 15. https:\/\/doi.org\/10.1186\/s12876-015-0396-x .","DOI":"10.1186\/s12876-015-0396-x"},{"key":"415_CR10","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1097\/PAS.0000000000000863","volume":"41","author":"Y Xue","year":"2017","unstructured":"Xue, Y. et al. Immunohistochemical classification of ampullary carcinomas: critical reappraisal fails to confirm prognostic relevance for recently proposed panels, and highlights MUC5AC as a strong prognosticator. Am. J. Surg. Pathol. 41, 865\u2013876 (2017).","journal-title":"Am. J. Surg. Pathol."},{"key":"415_CR11","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.celrep.2015.12.005","volume":"14","author":"MC Gingras","year":"2016","unstructured":"Gingras, M.-C. et al. Ampullary cancers harbor ELF3 tumor suppressor gene mutations and exhibit frequent WNT dysregulation. Cell Rep. 14, 907\u2013919 (2016).","journal-title":"Cell Rep."},{"key":"415_CR12","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.ccell.2015.12.012","volume":"29","author":"S Yachida","year":"2016","unstructured":"Yachida, S. et al. Genomic sequencing identifies ELF3 as a driver of ampullary carcinoma. Cancer Cell. 29, 229\u2013240 (2016).","journal-title":"Cancer Cell."},{"key":"415_CR13","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/modpathol.2013.185","volume":"27","author":"K Mikhitarian","year":"2014","unstructured":"Mikhitarian, K. et al. Epidermal growth factor receptor signaling pathway is frequently altered in ampullary carcinoma at protein and genetic levels. Mod. Pathol. 27, 665\u2013674 (2014).","journal-title":"Mod. Pathol."},{"key":"415_CR14","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.humpath.2015.11.009","volume":"50","author":"MJ Kwon","year":"2016","unstructured":"Kwon, M. J. et al. Low incidence of KRAS, BRAF, and PIK3CA mutations in adenocarcinomas of the ampulla of Vater and their prognostic value. Hum. Pathol. 50, 90\u2013100 (2016).","journal-title":"Hum. Pathol."},{"key":"415_CR15","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1038\/modpathol.2016.124","volume":"29","author":"MD Reid","year":"2016","unstructured":"Reid, M. D. et al. Ampullary carcinoma is often of mixed or hybrid histologic type: an analysis of reproducibility and clinical relevance of classification as pancreatobiliary versus intestinal in 232 cases. Mod. Pathol. 29, 1575\u20131585 (2016).","journal-title":"Mod. Pathol."},{"key":"415_CR16","doi-asserted-by":"publisher","first-page":"4231","DOI":"10.1200\/JCO.2007.10.9744","volume":"25","author":"M Svrcek","year":"2007","unstructured":"Svrcek, M. et al. Specific clinical and biological features characterize inflammatory bowel disease\u2013associated colorectal cancers showing microsatellite instability. J. Clin. Oncol. 25, 4231\u20134238 (2007).","journal-title":"J. Clin. Oncol."},{"key":"415_CR17","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","volume":"25","author":"AC Wolff","year":"2006","unstructured":"Wolff, A. C. et al. American Society of Clinical Oncology\/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. J. Clin. Oncol. 25, 118\u2013145 (2006).","journal-title":"J. Clin. Oncol."},{"key":"415_CR18","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.ejso.2018.02.008","volume":"44","author":"Z Jin","year":"2018","unstructured":"Jin, Z. et al. Prognostic factors and benefits of adjuvant therapy after pancreatoduodenectomy for ampullary adenocarcinoma: Mayo Clinic experience. Eur. J. Surg. Oncol. 44, 677\u2013683 (2018).","journal-title":"Eur. J. Surg. Oncol."},{"key":"415_CR19","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1097\/PAS.0000000000000278","volume":"38","author":"T Ushiku","year":"2014","unstructured":"Ushiku, T., Arnason, T., Fukayama, M. & Lauwers, G. Y. Extra-ampullary duodenal adenocarcinoma. Am. J. Surg. Pathol. 38, 1484\u20131493 (2014).","journal-title":"Am. J. Surg. Pathol."},{"key":"415_CR20","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.surg.2013.12.003","volume":"155","author":"A Ruzzenente","year":"2014","unstructured":"Ruzzenente, A. et al. A novel serum marker for biliary tract cancer: Diagnostic and prognostic values of quantitative evaluation of serum mucin 5AC (MUC5AC). Surgery 155, 633\u2013639 (2014).","journal-title":"Surgery"},{"key":"415_CR21","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1111\/his.12693","volume":"67","author":"YK Kim","year":"2015","unstructured":"Kim, Y. K. et al. MUC5AC and MUC5B enhance the characterization of mucinous adenocarcinomas of the lung and predict poor prognosis. Histopathology 67, 520\u2013528 (2015).","journal-title":"Histopathology"},{"key":"415_CR22","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nature11252","volume":"487","author":"DM Muzny","year":"2012","unstructured":"Muzny, D. M. et al. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330\u2013337 (2012).","journal-title":"Nature"},{"key":"415_CR23","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ccell.2017.07.007","volume":"32","author":"BJ Raphael","year":"2017","unstructured":"Raphael, B. J. et al. Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell. 32, 185\u2013203.e13 (2017).","journal-title":"Cancer Cell."},{"key":"415_CR24","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1016\/j.ejca.2014.04.007","volume":"50","author":"A Laforest","year":"2014","unstructured":"Laforest, A. et al. ERBB2 gene as a potential therapeutic target in small bowel adenocarcinoma. Eur. J. Cancer 50, 1740\u20131746 (2014).","journal-title":"Eur. J. Cancer"},{"key":"415_CR25","doi-asserted-by":"crossref","first-page":"58001","DOI":"10.18632\/oncotarget.11156","volume":"7","author":"BJ Kim","year":"2016","unstructured":"Kim, B. J., Jang, H. J., Kim, J. H., Kim, H. S. & Lee, J. KRAS mutation as a prognostic factor in ampullary adenocarcinoma: a meta-analysis and review. Oncotarget 7, 58001 (2016).","journal-title":"Oncotarget"},{"key":"415_CR26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/jso.24274","volume":"114","author":"E Asano","year":"2016","unstructured":"Asano, E. et al. Phenotypic characterization and clinical outcome in ampullary adenocarcinoma: Characterization of Ampullary Cancer. J. Surg. Oncol. 114, 119\u2013127 (2016).","journal-title":"J. Surg. Oncol."},{"key":"415_CR27","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.3109\/00365521.2015.1046912","volume":"50","author":"E Haraldsson","year":"2015","unstructured":"Haraldsson, E. et al. Endoscopic papillectomy and KRAS expression in the treatment of adenoma in the major duodenal papilla. Scand. J. Gastroenterol. 50, 1419\u20131427 (2015).","journal-title":"Scand. J. Gastroenterol."},{"key":"415_CR28","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1097\/SLA.0000000000001999","volume":"267","author":"A Mafficini","year":"2018","unstructured":"Mafficini, A. et al. Ampulla of Vater carcinoma: sequencing analysis identifies TP53 status as a novel independent prognostic factor and potentially actionable ERBB, PI3K, and WNT pathways gene mutations. Ann. Surg. 267, 149\u2013156 (2018).","journal-title":"Ann. Surg."},{"key":"415_CR29","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.surg.2014.08.092","volume":"157","author":"NP Valsangkar","year":"2015","unstructured":"Valsangkar, N. P. et al. Survival in ampullary cancer: Potential role of different KRAS mutations. Surgery 157, 260\u2013268 (2015).","journal-title":"Surgery"},{"key":"415_CR30","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1097\/MPA.0b013e31823cd9df","volume":"41","author":"NA Schultz","year":"2012","unstructured":"Schultz, N. A. et al. Frequencies and prognostic role of KRAS and BRAF mutations in patients with localized pancreatic and ampullary adenocarcinomas. Pancreas 41, 759\u2013766 (2012).","journal-title":"Pancreas"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-019-0415-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-019-0415-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-019-0415-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:04:28Z","timestamp":1684616668000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-019-0415-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,6]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["415"],"URL":"https:\/\/doi.org\/10.1038\/s41416-019-0415-8","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,6]]},"assertion":[{"value":"30 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Geraldine Perkins received a grant from Merck Serono, and reports honoraria from Servier and Sanofi. Thierry Andr\u00e9 has served in a consulting\/advisory role for Roche, Amgen, Bristol-Myers Squibb, and MSD Oncology. Julien Taieb reports honoraria from Amgen, Baxalta, Celgene, Eli Lilly, Merck KGgA, Roche\/Genentech, Sanofi, and Servier, and a consultancy or advisory role with Amgen, Baxalta, Celgene, Eli Lilly, Merck KGgA, Roche\/Genentech, Sanofi, and Servier. Magali Svrcek, Cecile Bouchet Doumenq, Thibault Voron, Orianne Colussi, Clotilde Debove, Fatiha Merabtene, Sylvie Dumont, Alain Sauvanet, Pascal Hammel, Jerome Cros, Jean-Baptiste Bachet, Armelle Bardier, Richard Douard, Tchao Meatchi, Frederique Peschaud, Jean-Francois Emile, Isabelle Cojean-Zelek and Pierre Laurent-Puig declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Data and materials are available on request.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Acquisition of data and biological material was approved by the Ile-de-France ethics committee number 4. The study was performed in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This work was supported in part by ARCAD (Aide et Recherche en Canc\u00e9rologie Digestive).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors gave final approval on the version to be published.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Note"}}]}}